With positive data from two validation studies in hand, diagnostics firm Pronota is prepping its acute heart failure protein biomarker CD146 for a 2014 launch.

The company announced last week that two independent validation studies comprising more than 500 patients demonstrated the marker significantly improved diagnosis of acute heart failure in patients presenting with shortness of breath.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.